The implant helps native meniscal tissue regenerate instead of needing to cut or replace it, according to a news release. An animal study also found that RejuvaKnee could withstand full weight bearing, and the knee returned to full range of motion after three months of implantation.
RejuvaKnee is the 60th FDA-cleared product from Regenity Biosciences.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.